Citizens Jmp Lowers Structure Therapeutics (NASDAQ:GPCR) Price Target to $113.00

Structure Therapeutics (NASDAQ:GPCR) had its price target lowered by equities researchers at Citizens Jmp from $120.00 to $113.00 in a report issued on Friday,Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp’s target price indicates a potential upside of 75.13% from the stock’s previous close.

Several other research firms have also issued reports on GPCR. Citigroup restated an “outperform” rating on shares of Structure Therapeutics in a research report on Friday, December 12th. Stifel Nicolaus upped their price objective on shares of Structure Therapeutics from $50.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, December 8th. JPMorgan Chase & Co. lifted their target price on Structure Therapeutics from $65.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, January 22nd. HC Wainwright lifted their price objective on Structure Therapeutics from $60.00 to $90.00 and gave the company a “buy” rating in a report on Friday, December 19th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $105.50.

Structure Therapeutics Price Performance

NASDAQ GPCR opened at $64.53 on Friday. The stock’s 50 day simple moving average is $75.45 and its 200 day simple moving average is $46.22. Structure Therapeutics has a one year low of $13.22 and a one year high of $94.90. The firm has a market cap of $4.56 billion, a PE ratio of -52.89 and a beta of -2.06.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.14). As a group, equities analysts expect that Structure Therapeutics will post -0.82 earnings per share for the current year.

Hedge Funds Weigh In On Structure Therapeutics

A number of large investors have recently modified their holdings of the business. Envestnet Asset Management Inc. bought a new stake in Structure Therapeutics during the second quarter worth about $221,000. Assetmark Inc. boosted its holdings in shares of Structure Therapeutics by 39.9% in the 2nd quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock valued at $60,000 after buying an additional 820 shares during the last quarter. Bank of Montreal Can increased its holdings in Structure Therapeutics by 9.1% during the second quarter. Bank of Montreal Can now owns 58,073 shares of the company’s stock worth $1,224,000 after buying an additional 4,838 shares during the last quarter. Quinn Opportunity Partners LLC raised its position in Structure Therapeutics by 90.9% during the second quarter. Quinn Opportunity Partners LLC now owns 42,000 shares of the company’s stock worth $871,000 after acquiring an additional 20,000 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its stake in Structure Therapeutics by 29.1% in the second quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock valued at $92,000 after acquiring an additional 994 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.